Research ArticleDrug Discovery and Translational Medicine
GSK356278, a Potent, Selective, Brain-Penetrant Phosphodiesterase 4 Inhibitor That Demonstrates Anxiolytic and Cognition-Enhancing Effects without Inducing Side Effects in Preclinical Species
A. Richard Rutter, Alessandro Poffe, Palmina Cavallini, T. Gregg Davis, Jessica Schneck, Michele Negri, Elena Vicentini, Dino Montanari, Roberto Arban, Frank A. Gray, Ceri H. Davies and Paul B. Wren
Journal of Pharmacology and Experimental Therapeutics July 2014, 350 (1) 153-163; DOI: https://doi.org/10.1124/jpet.114.214155
A. Richard Rutter
GlaxoSmithKline, Discovery Medicine, Stevenage, Herts, United Kingdom (F.A.G., P.B.W.); GlaxoSmithKline, Neural Pathways Discovery Performance Unit, Biopolis, Singapore (A.R.R., C.H.D.); GlaxoSmithKline, Neurosciences Centre of Excellence for Drug Discovery, Verona, Italy (A.P., P.C., M.N., E.V., D.M., R.A.); GlaxoSmithKline, Molecular Discovery Research, Collegeville, Pennsylvania (J.S.); and GlaxoSmithKline, Respiratory Centre of Excellence for Drug Discovery, King of Prussia, Pennsylvania (T.G.D.)
Alessandro Poffe
GlaxoSmithKline, Discovery Medicine, Stevenage, Herts, United Kingdom (F.A.G., P.B.W.); GlaxoSmithKline, Neural Pathways Discovery Performance Unit, Biopolis, Singapore (A.R.R., C.H.D.); GlaxoSmithKline, Neurosciences Centre of Excellence for Drug Discovery, Verona, Italy (A.P., P.C., M.N., E.V., D.M., R.A.); GlaxoSmithKline, Molecular Discovery Research, Collegeville, Pennsylvania (J.S.); and GlaxoSmithKline, Respiratory Centre of Excellence for Drug Discovery, King of Prussia, Pennsylvania (T.G.D.)
Palmina Cavallini
GlaxoSmithKline, Discovery Medicine, Stevenage, Herts, United Kingdom (F.A.G., P.B.W.); GlaxoSmithKline, Neural Pathways Discovery Performance Unit, Biopolis, Singapore (A.R.R., C.H.D.); GlaxoSmithKline, Neurosciences Centre of Excellence for Drug Discovery, Verona, Italy (A.P., P.C., M.N., E.V., D.M., R.A.); GlaxoSmithKline, Molecular Discovery Research, Collegeville, Pennsylvania (J.S.); and GlaxoSmithKline, Respiratory Centre of Excellence for Drug Discovery, King of Prussia, Pennsylvania (T.G.D.)
T. Gregg Davis
GlaxoSmithKline, Discovery Medicine, Stevenage, Herts, United Kingdom (F.A.G., P.B.W.); GlaxoSmithKline, Neural Pathways Discovery Performance Unit, Biopolis, Singapore (A.R.R., C.H.D.); GlaxoSmithKline, Neurosciences Centre of Excellence for Drug Discovery, Verona, Italy (A.P., P.C., M.N., E.V., D.M., R.A.); GlaxoSmithKline, Molecular Discovery Research, Collegeville, Pennsylvania (J.S.); and GlaxoSmithKline, Respiratory Centre of Excellence for Drug Discovery, King of Prussia, Pennsylvania (T.G.D.)
Jessica Schneck
GlaxoSmithKline, Discovery Medicine, Stevenage, Herts, United Kingdom (F.A.G., P.B.W.); GlaxoSmithKline, Neural Pathways Discovery Performance Unit, Biopolis, Singapore (A.R.R., C.H.D.); GlaxoSmithKline, Neurosciences Centre of Excellence for Drug Discovery, Verona, Italy (A.P., P.C., M.N., E.V., D.M., R.A.); GlaxoSmithKline, Molecular Discovery Research, Collegeville, Pennsylvania (J.S.); and GlaxoSmithKline, Respiratory Centre of Excellence for Drug Discovery, King of Prussia, Pennsylvania (T.G.D.)
Michele Negri
GlaxoSmithKline, Discovery Medicine, Stevenage, Herts, United Kingdom (F.A.G., P.B.W.); GlaxoSmithKline, Neural Pathways Discovery Performance Unit, Biopolis, Singapore (A.R.R., C.H.D.); GlaxoSmithKline, Neurosciences Centre of Excellence for Drug Discovery, Verona, Italy (A.P., P.C., M.N., E.V., D.M., R.A.); GlaxoSmithKline, Molecular Discovery Research, Collegeville, Pennsylvania (J.S.); and GlaxoSmithKline, Respiratory Centre of Excellence for Drug Discovery, King of Prussia, Pennsylvania (T.G.D.)
Elena Vicentini
GlaxoSmithKline, Discovery Medicine, Stevenage, Herts, United Kingdom (F.A.G., P.B.W.); GlaxoSmithKline, Neural Pathways Discovery Performance Unit, Biopolis, Singapore (A.R.R., C.H.D.); GlaxoSmithKline, Neurosciences Centre of Excellence for Drug Discovery, Verona, Italy (A.P., P.C., M.N., E.V., D.M., R.A.); GlaxoSmithKline, Molecular Discovery Research, Collegeville, Pennsylvania (J.S.); and GlaxoSmithKline, Respiratory Centre of Excellence for Drug Discovery, King of Prussia, Pennsylvania (T.G.D.)
Dino Montanari
GlaxoSmithKline, Discovery Medicine, Stevenage, Herts, United Kingdom (F.A.G., P.B.W.); GlaxoSmithKline, Neural Pathways Discovery Performance Unit, Biopolis, Singapore (A.R.R., C.H.D.); GlaxoSmithKline, Neurosciences Centre of Excellence for Drug Discovery, Verona, Italy (A.P., P.C., M.N., E.V., D.M., R.A.); GlaxoSmithKline, Molecular Discovery Research, Collegeville, Pennsylvania (J.S.); and GlaxoSmithKline, Respiratory Centre of Excellence for Drug Discovery, King of Prussia, Pennsylvania (T.G.D.)
Roberto Arban
GlaxoSmithKline, Discovery Medicine, Stevenage, Herts, United Kingdom (F.A.G., P.B.W.); GlaxoSmithKline, Neural Pathways Discovery Performance Unit, Biopolis, Singapore (A.R.R., C.H.D.); GlaxoSmithKline, Neurosciences Centre of Excellence for Drug Discovery, Verona, Italy (A.P., P.C., M.N., E.V., D.M., R.A.); GlaxoSmithKline, Molecular Discovery Research, Collegeville, Pennsylvania (J.S.); and GlaxoSmithKline, Respiratory Centre of Excellence for Drug Discovery, King of Prussia, Pennsylvania (T.G.D.)
Frank A. Gray
GlaxoSmithKline, Discovery Medicine, Stevenage, Herts, United Kingdom (F.A.G., P.B.W.); GlaxoSmithKline, Neural Pathways Discovery Performance Unit, Biopolis, Singapore (A.R.R., C.H.D.); GlaxoSmithKline, Neurosciences Centre of Excellence for Drug Discovery, Verona, Italy (A.P., P.C., M.N., E.V., D.M., R.A.); GlaxoSmithKline, Molecular Discovery Research, Collegeville, Pennsylvania (J.S.); and GlaxoSmithKline, Respiratory Centre of Excellence for Drug Discovery, King of Prussia, Pennsylvania (T.G.D.)
Ceri H. Davies
GlaxoSmithKline, Discovery Medicine, Stevenage, Herts, United Kingdom (F.A.G., P.B.W.); GlaxoSmithKline, Neural Pathways Discovery Performance Unit, Biopolis, Singapore (A.R.R., C.H.D.); GlaxoSmithKline, Neurosciences Centre of Excellence for Drug Discovery, Verona, Italy (A.P., P.C., M.N., E.V., D.M., R.A.); GlaxoSmithKline, Molecular Discovery Research, Collegeville, Pennsylvania (J.S.); and GlaxoSmithKline, Respiratory Centre of Excellence for Drug Discovery, King of Prussia, Pennsylvania (T.G.D.)
Paul B. Wren
GlaxoSmithKline, Discovery Medicine, Stevenage, Herts, United Kingdom (F.A.G., P.B.W.); GlaxoSmithKline, Neural Pathways Discovery Performance Unit, Biopolis, Singapore (A.R.R., C.H.D.); GlaxoSmithKline, Neurosciences Centre of Excellence for Drug Discovery, Verona, Italy (A.P., P.C., M.N., E.V., D.M., R.A.); GlaxoSmithKline, Molecular Discovery Research, Collegeville, Pennsylvania (J.S.); and GlaxoSmithKline, Respiratory Centre of Excellence for Drug Discovery, King of Prussia, Pennsylvania (T.G.D.)
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Research ArticleDrug Discovery and Translational Medicine
GSK356278, a Brain-Penetrant PDE4 Inhibitor
A. Richard Rutter, Alessandro Poffe, Palmina Cavallini, T. Gregg Davis, Jessica Schneck, Michele Negri, Elena Vicentini, Dino Montanari, Roberto Arban, Frank A. Gray, Ceri H. Davies and Paul B. Wren
Journal of Pharmacology and Experimental Therapeutics July 1, 2014, 350 (1) 153-163; DOI: https://doi.org/10.1124/jpet.114.214155
Research ArticleDrug Discovery and Translational Medicine
GSK356278, a Brain-Penetrant PDE4 Inhibitor
A. Richard Rutter, Alessandro Poffe, Palmina Cavallini, T. Gregg Davis, Jessica Schneck, Michele Negri, Elena Vicentini, Dino Montanari, Roberto Arban, Frank A. Gray, Ceri H. Davies and Paul B. Wren
Journal of Pharmacology and Experimental Therapeutics July 1, 2014, 350 (1) 153-163; DOI: https://doi.org/10.1124/jpet.114.214155
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement